Namrata S Patil

10PUBLICATIONS
48CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tissue engineeringApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 30, 2026
Combined circulating tumor antigen model demonstrates additional prognostic value in first-line treatment of non-small cell lung cancer.

|Jul 27, 2026
SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.

|Aug 20, 2024
Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.

Xiangnan Guan, Ruozhen Hu, Yoonha Choi

|May 30, 2024
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.

Xiangnan Guan, Ruozhen Hu, Yoonha Choi

|Mar 25, 2024
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy.

Xiao Li, Jeffrey Eastham, Jennifer M Giltnane

|Mar 14, 2024
Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.

Xiangnan Guan, Ruozhen Hu, Yoonha Choi

Pageof 2

Frequent Collaborators

6 joint publications

Melissa Johnson

5 joint publications

Barzin Y Nabet

5 joint publications

Byoung Chul Cho

4 joint publications

Patrick S Chang